Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy
Sponsor: Massachusetts General Hospital
Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with TUBB4A associated leukodystrophy.
Official title: An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy
Key Details
Gender
All
Age Range
4 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1
Start Date
2024-09-18
Completion Date
2026-06
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
Antisense oligonucleotide treatment (ASO)
Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States